Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate

BACKGROUND: In April 2015, the US Food and Drug Administration approved the first generic glatiramer acetate, Glatopa® (M356), as fully substitutable for Copaxone® 20 mg/mL for relapsing forms of multiple sclerosis (MS). This approval was accomplished through an Abbreviated New Drug Applica-tion tha...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:CNS Neurol Disord Drug Targets
Huvudupphovsmän: D’Alessandro, Josephine, Garofalo, Kevin, Zhao, Ganlin, Honan, Christopher, Duffner, Jay, Capila, Ishan, Fier, Ian, Kaundinya, Ganesh, Kantor, Daniel, Ganguly, Tanmoy
Materialtyp: Artigo
Språk:Inglês
Publicerad: Bentham Science Publishers 2017
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5684786/
https://ncbi.nlm.nih.gov/pubmed/28240190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1871527316666170223162747
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk